July 25, 2022
VIA EDGAR TRANSMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Mail Stop 4720
Washington, DC 20549
Attention: Conlon Danberg
Ayala Pharmaceuticals, Inc.
Request for Withdrawal of Registration Statement on Form
File No. 333-266072
Dear Mr. Danberg,
Pursuant to Rule 477 promulgated under the Securities Act of 1933,
as amended (the “Securities Act”), Ayala Pharmaceuticals, Inc. (the
“Company”) hereby requests that the Registration Statement on Form
S-1 (File No. 333-266072),
initially filed with the Securities and Exchange Commission (the
“Commission”) on July 8, 2022 (as amended, the
“Registration Statement”) and all exhibits thereto, be withdrawn
effective as of the date hereof or at the earliest practicable date
The Company is seeking withdrawal of the Registration Statement
because it is no longer pursuing a public offering of securities at
this time. The Registration Statement has not been declared
effective by the Commission and no securities have been issued or
sold under the Registration Statement.
The Company acknowledges that no refund will be made for fees paid
to the Commission in connection with the filing of the Registration
Statement. However, in accordance with Rule 457(p) under the
Securities Act, the Company requests that all fees paid to the
Commission in connection with the filing of the Registration
Statement be credited for future use.
Please direct any questions or comments regarding this
correspondence to our counsel, Keith Halverstam of
Latham & Watkins LLP, at (212) 906-1761, or in his absence,
Jennifer Yoon at (617) 880-4540,
Thank you for your assistance in this matter.
|Very truly yours,
|Ayala Pharmaceuticals, Inc.
||Name: Yossi Maimon
||Title: Chief Financial Officer
Peter N. Handrinos, Esq., Latham & Watkins
Keith L. Halverstam, Esq., Latham & Watkins LLP
Jennifer Yoon, Esq., Latham & Watkins LLP